In high-risk type 2 diabetes, once-daily oral semaglutide 14 mg cut major adverse cardiovascular events versus placebo in the SOUL trial, with no kidney benefit shown. PICO summary and expert commentary.
Browsing: Diabetes
Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
A single-centre Egyptian RCT found the Diabetes Conversation Map programme improved diabetes knowledge, self-management, and self-efficacy questionnaire scores versus standard education (p < 0.001), with no clinical endpoints reported. PICO summary and expert commentary.
A post-hoc ACCORD-BP analysis of 307 patients with type 2 diabetes and prior stroke links intensive SBP control below 120 mmHg to lower MACE risk. PICO summary and expert commentary.
A randomised controlled trial of a psychosocial weight-management programme in overweight or obese pregnant women improved diet and activity but not gestational diabetes, preeclampsia, or caesarean rates. PICO summary and expert commentary.
A multicentre randomised trial testing a CBT-based WeChat dietary programme against standard care for postprandial glucose and pregnancy outcomes in gestational diabetes. PICO summary and expert commentary.
An EXSCEL post hoc simulation and mediation analysis showing conventional risk-factor changes explain only a modest share of once-weekly exenatide’s cardiovascular effects. PICO summary and expert commentary.
A manufacturer-sponsored secondary analysis found a digital diabetes logbook nearly doubled the odds of reaching HbA1c 6.5% or below at 3 months, with associated real-world glucose reductions. PICO summary and expert commentary.
A small single-blind RCT found that a family-centered empowerment program raised illness acceptance and self-management scores at six weeks in adults with type 2 diabetes. PICO summary and expert commentary.
A one-year randomised controlled trial testing whether pharmacist-led collaborative care improves EQ-5D quality of life and HbA1c versus routine care in adults with diabetes. PICO summary and expert commentary.
A Phase 1 crossover study in healthy Korean volunteers found the enavogliflozin/gemigliptin fixed-dose combination pharmacokinetically equivalent to the separate tablets, with food not altering enavogliflozin exposure. PICO summary and expert commentary.